Abstract
No public abstract is available from the verified source records.
Isaac Solomon, Tammy Pham, Alena Pauley, Loren Mell, Assuntina G. Sacco, Theresa Guo
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Salvage surgery in recurrent oral squamous cell carcinoma
2021
Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas
10.1002/hed.20502 · 2007
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer
10.1016/j.oraloncology.2012.07.015 · 2013
The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx
10.1002/cncr.24595 · 2009
Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer
10.1002/lary.20743 · 2010
Salvage surgery for recurrent squamous cell carcinoma of the head and neck: Systematic review and meta-analysis
10.1002/hed.26898 · 2022
Fluorescent guided sentinel lymph mapping of the oral cavity with fluorescent-labeled tilmanocept
10.1002/lary.31014 · 2024
Estimating survival after salvage surgery for recurrent oral cavity cancer
10.1001/jamaoto.2017.0001 · 2017
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
10.1056/nejmoa1602252 · 2016
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
10.1002/cncr.31717 · 2018
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
10.1016/s1470-2045(16)30066-3 · 2016
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
10.1016/s0140-6736(19)32591-7 · 2019
Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study
10.1002/hed.27162 · 2022
Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: The emergence of immunotherapy
10.21037/tcr-23-1 · 2023
10.1016/j.radonc.2014.06.003
10.1016/j.radonc.2014.06.003
Unresolved referenced work
Kept as external metadata until matched
Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer
10.1016/j.radonc.2024.110278 · 2024
Optimising (re-)irradiation for locally recurrent head and neck cancer: Impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes—a single centre analysis
10.1186/s13014-024-02570-y · 2025
Reirradiation of head and neck cancers with proton therapy: Outcomes and analyses
10.1016/j.ijrobp.2016.03.053 · 2016
Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell Carcinoma
10.1001/jamanetworkopen.2022.50607 · 2023
Clinical outcome of salvage surgery in patients with recurrent oral cavity cancer: A systematic review and meta-analysis
10.1002/hed.27928 · 2024
10.1016/s1470-2045(21)00136-4
10.1016/s1470-2045(21)00136-4
Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell Carcinoma
10.1158/1078-0432.ccr-21-3849 · 2022
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial
2025
Ficerafusp Alfa (BCA101) with pembrolizumab for recurrent or metastatic head and neck squamous cell Carcinoma: Two-year results of an expansion cohort of a phase I/Ib Trial
10.1200/jco-25-02027 · 2026
10.1200/jco-26-01042
10.1200/jco-26-01042
No additional external references are available.